295 related articles for article (PubMed ID: 28395507)
1. Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea.
Choi YJ; Kim N; Jang IJ; Cho JY; Nam RH; Park JH; Jo HJ; Yoon H; Shin CM; Park YS; Lee DH; Jung HC
Gut Liver; 2017 Jul; 11(4):504-511. PubMed ID: 28395507
[TBL] [Abstract][Full Text] [Related]
2. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
[TBL] [Abstract][Full Text] [Related]
3. Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial.
Parri MS; Gianetti J; Dushpanova A; Della Pina F; Saracini C; Marcucci R; Giusti B; Berti S
Int J Cardiol; 2013 Sep; 167(5):2177-81. PubMed ID: 22727972
[TBL] [Abstract][Full Text] [Related]
4. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Neubauer H; Engelhardt A; Krüger JC; Lask S; Börgel J; Mügge A; Endres HG
J Cardiovasc Pharmacol; 2010 Jul; 56(1):91-7. PubMed ID: 20410834
[TBL] [Abstract][Full Text] [Related]
5. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Cuisset T; Frere C; Quilici J; Poyet R; Gaborit B; Bali L; Brissy O; Morange PE; Alessi MC; Bonnet JL
J Am Coll Cardiol; 2009 Sep; 54(13):1149-53. PubMed ID: 19761935
[TBL] [Abstract][Full Text] [Related]
6. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.
Kasprzak M; Koziński M; Bielis L; Boinska J; Plazuk W; Marciniak A; Budzyński J; Siller-Matula J; Rość D; Kubica J
Cardiol J; 2009; 16(6):535-44. PubMed ID: 19950090
[TBL] [Abstract][Full Text] [Related]
7. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
[TBL] [Abstract][Full Text] [Related]
8. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
Fontes-Carvalho R; Albuquerque A; Araújo C; Pimentel-Nunes P; Ribeiro VG
Eur J Gastroenterol Hepatol; 2011 May; 23(5):396-404. PubMed ID: 21464720
[TBL] [Abstract][Full Text] [Related]
9. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test.
Tazaki J; Jinnai T; Tada T; Kato Y; Makiyama T; Ikeda T; Yamane K; Naruse Y; Takahashi K; Watanabe H; Kimura T; Horiuchi H
J Atheroscler Thromb; 2012; 19(2):186-93. PubMed ID: 22166969
[TBL] [Abstract][Full Text] [Related]
10. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
12. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study.
Arbel Y; Birati EY; Finkelstein A; Halkin A; Kletzel H; Abramowitz Y; Berliner S; Deutsch V; Herz I; Keren G; Banai S
Clin Cardiol; 2013 Jun; 36(6):342-6. PubMed ID: 23630016
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study.
Ferreiro JL; Ueno M; Tomasello SD; Capodanno D; Desai B; Dharmashankar K; Seecheran N; Kodali MK; Darlington A; Pham JP; Tello-Montoliu A; Charlton RK; Bass TA; Angiolillo DJ
Circ Cardiovasc Interv; 2011 Jun; 4(3):273-9. PubMed ID: 21521834
[TBL] [Abstract][Full Text] [Related]
14. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
[TBL] [Abstract][Full Text] [Related]
15. [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel.
Furuta T; Iwaki T; Umemura K
Eur J Clin Pharmacol; 2010 May; 66(5):457-63. PubMed ID: 20349052
[TBL] [Abstract][Full Text] [Related]
16. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Mizia-Stec K; Haberka M; Mizia M; Lasota B; Kunecki M; Gieszczyk K; Chmiel A; Najda J; Kyrcz-Krzemień S; Gąsior Z
Pharmacol Rep; 2012; 64(2):360-8. PubMed ID: 22661187
[TBL] [Abstract][Full Text] [Related]
17. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Mărginean A; Bănescu C; Moldovan V; Scridon A; Mărginean M; Bălaşa R; Maier S; Ţăruşi M; Dobreanu M
Clin Appl Thromb Hemost; 2017 Apr; 23(3):255-265. PubMed ID: 26873108
[TBL] [Abstract][Full Text] [Related]
18. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
19. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M
Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
